-INCLUSION CRITIERIA:

          1. Measurable (per RECIST v1.1 criteria), metastatic, or unresectable malignancy
             expressing G12D mutated KRAS as assessed by one of the following methods: RT-PCR on
             tumor tissue, tumor DNA sequencing, or any other CLIA-certified laboratory test on

             resected tissue. Patients shown to have tumors expressing G12D mutated NRAS and HRAS
             will also be eligible as these oncogenes share complete amino acid homology with G12D
             mutated KRAS for their first 80 N-terminal amino acids, completely encompassing the
             target epitope.

          2. Patients must be HLA-A*11:01 positive as confirmed by the NIH Department of
             Transfusion Medicine.

          3. Confirmation of the diagnosis of cancer by the NCI Laboratory of Pathology.

          4. Patients must:

             - Have previously received standard systemic therapy for their advanced cancer and
             have been either non-responders or have recurred. Specifically:

               -  Patients with metastatic colorectal cancer must have had at least two systemic
                  chemotherapy regimens that include 5FU, leucovorin, bevacizumab, oxaliplatin, and
                  irinotecan (or similar agents), or have contraindications to receiving those
                  medications.

               -  Patients with pancreatic cancer must have received gemcitabine, 5FU, and
                  oxaliplatin (or similar agents), or have contraindications to receiving those
                  medications.

               -  Patients with non-small cell lung cancer (NSCLC) must have had appropriate
                  targeted therapy as indicated by abnormalities in ALK, EGFR, or expression of
                  PDL-1. Other patients must have had platinum-based chemotherapy.

               -  Patients with ovarian cancer or prostate cancer must have had approved first-line
                  chemotherapy.

             OR

             -have declined standard treatment

          5. Patients with 3 or fewer brain metastases that are < 1 cm in diameter and asymptomatic
             are eligible. Lesions that have been treated with stereotactic radiosurgery must be
             clinically stable for one month after treatment for the patient to be eligible.
             Patients with

             surgically resected brain metastases are eligible.

          6. Age greater than or equal to 18 years and less than or equal to 70 years.

          7. Clinical performance status of ECOG 0 or 1

          8. Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study and for four months after treatment.

          9. Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the treatment on the fetus.

         10. Serology

             -Seronegative for HIV antibody. (The experimental treatment being evaluated in this
             protocol depends on an intact immune system. Patients who are HIV seropositive may
             have decreased immune-competence and thus be less responsive to the experimental

             treatment and more susceptible to its toxicities.)

             -Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If
             hepatitis C antibody test is positive, then patient must be tested for the presence of
             antigen by RT-PCR and be HCV RNA negative

         11. Hematology

               -  ANC > 1000/mm^3 without the support of filgrastim

               -  WBC greater than or equal to 3000/mm^3

               -  Platelet count greater than or equal to 100,000/mm^3

               -  Hemoglobin > 8.0 g/dL. Subjects may be transfused to reach this cut-off.

         12. Chemistry

               -  Serum ALT/AST less than or equal to 5.0 x ULN

               -  Serum creatinine less than or equal to 1.6 mg/dL

               -  Total bilirubin less than or equal to 1.5 mg/dL, except in patients with Gilbert
                  s Syndrome, who must have a total bilirubin < 3.0 mg/dL.

         13. More than four weeks must have elapsed since completion of any prior systemic therapy
             an enrollment.

             Note: Patients may have undergone minor surgical procedures or limited field
             radiotherapy within the four weeks before enrollment, as long as related major organ
             toxicities have recovered to grade 1 or less

         14. Ability of subject to understand and the willingness to sign a written informed
             consent document.

         15. Willing to sign a durable power of attorney.

         16. Subjects must be co-enrolled on the NCI-SB cell harvest protocol 03-C-0277 (Cell
             Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols).

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Concurrent systemic steroid therapy.

          3. Active systemic infections requiring anti-infective treatment, coagulation disorders,
             or any other active or uncompensated major medical illnesses.

          4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          5. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased
             immunecompetence may be less responsive to the experimental treatment and more
             susceptible

             to its toxicities.)

          6. History of severe immediate hypersensitivity reaction to cyclophosphamide,
             fludarabine, or aldesleukin.

          7. History of coronary revascularization or ischemic symptoms.

          8. Documented LVEF less than or equal to 45% tested in patients:

               -  Age greater than or equal to 65 years

               -  With clinically significant atrial and/or ventricular arrhythmias, including but
                  not limited to: atrial fibrillation, ventricular tachycardia, second- or
                  third-degree heart block, or have a history of ischemic heart disease and/or
                  chest pain.

          9. Documented FEV1 less than or equal to 50% predicted in patients with:

               -  A prolonged history of cigarette smoking (greater than or equal to 20 pack-year
                  smoking history, with cessation within the past two years).

               -  Symptoms of respiratory dysfunction.

         10. Patients who are receiving any other investigational agents.